Program
ceftobiprole medocaril
Also written as “Ceftobiprole medocaril”, “Ceftobiprole medocaril sodium” and “Ceftobiprole Medocaril”.
Its studies are mostly in Community-Acquired Pneumonia · Staphylococcal Skin Infections · Endocarditis, Bacterial · Staphylococcal Infections · Neonatal Sepsis, led by 2 companies.
Drug pageCeftobiprole medocaril: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Basilea Pharmaceuticaits history only | 100 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| ISTx | 11 open or running | phase 3since Oct 19, 2026 | Oct 19, 2026 | Oct 31, 2028phase 3 · NCT07929493 |
Also a collaborator on its studies: Innoviva Specialty Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ISTx only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2026First study: phase 3 study in Endocarditis, BacterialFirst studyNCT07929493 · 60 planned
Ahead
- Oct 31, 2028Primary completion: phase 3 study in Endocarditis, BacterialNCT07929493
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Penicillin-binding protein 1 inhibitor; Penicillin-binding protein 2 inhibitor; Penicillin-binding protein inhibitor; Penicillin-binding protein 4 inhibitor”ChEMBL 37, by rule
Studies
The one study ISTx leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07929493Endocarditis, Bacterial | 3 | Not yet recruiting | Oct 31, 2028 | 60 |
How it is read
Names in the registry
- “Ceftobiprole medocaril”, 5 entries
- “ceftobiprole medocaril”, 4 entries
- “Ceftobiprole medocaril sodium”, 1 entry
- “Ceftobiprole Medocaril”, 1 entry
Conditions, from the studies’ own filings
- Community-Acquired Pneumonia, 2 studies
- Staphylococcal Skin Infections, 2 studies
- Endocarditis, Bacterial, 1 study
- Staphylococcal Infections, 1 study
- Neonatal Sepsis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.